Apellis Pharmaceuticals Inc (APLS)vsargenx NV ADR (ARGX)
APLS
Apellis Pharmaceuticals Inc
$17.72
+2.84%
HEALTHCARE · Cap: $2.27B
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 322% more annual revenue ($4.24B vs $1.00B). ARGX leads profitability with a 30.5% profit margin vs 2.2%. ARGX trades at a lower P/E of 34.6x. ARGX earns a higher WallStSmart Score of 63/100 (C+).
APLS
Avoid30
out of 100
Grade: F
ARGX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1728.7%
Fair Value
$1.22
Current Price
$17.72
$16.50 premium
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
2.2% margin — thin
Elevated debt levels
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : APLS
APLS has a balanced fundamental profile.
Bull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bear Case : APLS
The primary concerns for APLS are EPS Growth, Return on Equity, Profit Margin. A P/E of 98.4x leaves little room for execution misses. Thin 2.2% margins leave little buffer for downturns.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
APLS profiles as a value stock while ARGX is a growth play — different risk/reward profiles.
APLS carries more volatility with a beta of 0.29 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 30/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Apellis Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.
Visit Website →argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?